The growing number of disease-modifying medications approved for multiple sclerosis (MS) treatment is a significant step forward and provides new options for our patients. These medications, however, have differing efficacy and risk profiles. Although accurate predictors of efficacy are not available, treatment choices can be guided by patient-specific risk stratification. The use of risk mitigation strategies can help clinicians tailor MS treatment recommendations for individual patients.
Address correspondence to Dr Daniel Ontaneda, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, U-10, Cleveland, OH 44195, firstname.lastname@example.org.
Relationship Disclosure: Dr Ontaneda has served as a consultant or speaker for Acorda Therapeutics, Biogen Idec, and Novartis, and receives research support from the National Multiple Sclerosis Society and the NIH. Dr Fox serves as a consultant for Allozyne, Inc; Avanir Pharmaceuticals, Inc; Biogen Idec; Novartis; Questcor Pharmaceuticals, Inc; and Teva Neuroscience; and receives research support from Novartis.
Unlabeled Use of Products/Investigational Use Disclosure: Drs Ontaneda and Fox discuss mitigation strategies for alemtuzumab, which is not currently approved for the treatment of multiple sclerosis.